<DOC>
	<DOCNO>NCT01233869</DOCNO>
	<brief_summary>This purpose study determine bosutinib reduces rate kidney enlargement subject autosomal dominant polycystic kidney disease ( ADPKD ) enter study total kidney volume great equal 750 cc eGFR great equal 60 mL/min/1.73m2 .</brief_summary>
	<brief_title>Bosutinib For Autosomal Dominant Polycystic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney , Autosomal Dominant</mesh_term>
	<criteria>Males female , 18 50 year old time consent . Documented diagnosis ADPKD ( PKD1 PKD2 genotype allow ) . Total kidney volume ≥ 750 cc , measure centrally evaluate MRI . eGFR &lt; 60 mL/min/1.73m2 . Uncontrolled hypertension ( define systolic blood pressure ≥140 diastolic blood pressure ≥90 mm Hg ) . Any previous exposure bosutinib test article receipt polycystic kidney disease ( PKD ) therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Bosutinib</keyword>
	<keyword>Autosomal Dominant Polycystic Kidney Disease</keyword>
</DOC>